Note 1. Nature of Business Tyme Technologies, Inc. (TYME) is a Delaware corporation headquartered in New York, NY, with wholly-owned subsidiaries, Tyme Inc. and Luminant Biosciences, LLC (Luminant) (collectively, the Company). Prior to 2014, Luminant conducted the initial research and development of the Companys therapeutic platform. Since January 1, 2014, the majority of the Companys research, development and other business activities have been conducted by Tyme Inc., which was incorporated in Delaware in 2013. On October 27, 2016, the Board of Directors of TYME approved a change in fiscal year end from December 31 to March 31 of each year. The Company is a clinical stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across many tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Companys therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the bodys natural immune system. The Company has ongoing IND-enabled Phase II clinical trials in metastatic pancreatic cancer and biomarker recurrent prostate cancer. In September 2018, the Company announced an investigator-initiated Phase II trial of SM-88 in patients with previously treated metastatic sarcoma. In addition, on October 9, 2018, the Company entered into a Clinical Research Funding and Drug Supply Agreement with the Pancreatic Cancer Action Network, Inc., a non-profit tax exempt organization (PanCAN), whereby SM-88 will be included as an experimental arm in the Precision Promise adaptive pivotal trial platform sponsored by PanCAN. The Company is actively evaluating the expansion of its clinical programs to other types of cancer and continues to pursue the development of oncology drug candidates in addition to SM-88, its lead clinical program. The accompanying condensed consolidated financial statements include the results of operations of TYME and its wholly-owned subsidiaries. Liquidity The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. During fiscal year 2018, the Company raised gross proceeds of approximately $32.1 million through the issuance of its common stock, par value $0.0001 per share (Common Stock). Most recently in March 2018, the Company raised aggregate gross proceeds of $23.3 million before underwriting discounts and commissions and expenses of the offering through an underwritten public offering. Previously on November 2, 2017, the Company entered into an equity distribution agreement (Equity Distribution Agreement) with Canaccord Genuity Inc. (Canaccord), to commence an at-the-market offering (the ATM Financing Facility) pursuant to which the Company may, from time to time, subject to certain rules and regulations, sell shares of the Companys Common Stock having an aggregate offering price up to $30.0 million, through Canaccord, as the Companys sales agent. In the year ended March 31, 2018, the Company raised approximately $6.2 million in aggregate gross proceeds before commissions and expenses through the ATM Financing Facility and paid Canaccord aggregate commissions of $0.3 million. For the nine months ended December 31 , 2018, the Company raised approximately $4.2 million in aggregate gross proceeds before commissions and expenses through the ATM Financing Facility and paid Canaccord aggregate commissions of $0.1 million. At December 31 , 2018, there remained approximately $19.6 million of availability to sell shares through the facility. On October 25, 2018, the Company decided to discontinue use of the ATM Financing Facility for the remainder of calendar year 2018, to be reassessed in calendar year 2019. The Company has concluded it intends to reopen the ATM Financing Facility for potential use shortly after the filing of this Form 10-Q (see Part 2. Item 5. Other Information). For the nine months ended December 31, 2018, the Company had negative cash flow from operations of $16.1 million and net loss of $21.8 million, which included $6.7 million of non-cash expenses, primarily non-cash equity compensation expense. For the three months ended December 31, 2018, the Company had negative cash flow from operations of $5.2 million and net loss of $8.0 million, which included $2.0 million of non-cash expenses, primarily non-cash equity compensation expense. As of December 31, 2018, the Company had working capital of approximately $14.3 million. Management has concluded that substantial doubt does not exist regarding the Companys ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Companys assessment of qualitative and quantitative conditions and events, considered in the aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Companys operations, and potential adverse conditions or events as of the issuance date of these financial statements. The Company has developed an operational plan that manages expenses and delays initiation of certain operational initiatives to focus on core programs if appropriate funding is not available.